M Alvarez-Camacho1, S Gonella2,3, S Ghosh4, C Kubrak5,6, R A Scrimger7, K P Chu7, W V Wismer8. 1. Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada. 2. Dipartimento di Sanità Pubblica e Medicina di Comunità, Università degli Studi di Verona, Verona, Italy. 3. Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Università degli Studi di Torino, Turin, Italy. 4. Division of Medical Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada. 5. Department of Surgery, University of Alberta Hospital, Edmonton, AB, Canada. 6. Outpatient Department, Royal Alexandra Hospital, Edmonton, AB, Canada. 7. Department of Radiation Oncology, Cross Cancer Institute, Edmonton, AB, Canada. 8. Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada. wwismer@ualberta.ca.
Abstract
PURPOSE: Taste and smell alterations (TSAs) are among the most frequent and troublesome symptoms reported by head and neck cancer (HNC) patients after treatment. Little is known about the relationship between TSAs and quality of life (QoL) among HNC patients. The aim of this study was to determine the effect of TSAs on overall QoL among tube-fed and orally fed HNC patients before treatment, at end of treatment and at 2.5-month follow-up. METHODS: Data were collected in a longitudinal study prior to treatment (n = 126), at end of treatment (n = 100) and at 2.5-month follow-up (n = 85). Chemosensory Complaint Score (CCS) and the University of Washington Quality of Life Questionnaire version 3 were used to assess TSAs and QoL, respectively. Generalized estimated equation modeling was used to estimate the effect of CCS on QoL. RESULTS: At end of treatment, QoL and CCS had declined for both tube-fed and orally fed patients and thereafter improved, but not to pre-treatment levels. Neither QoL nor CCS mean scores were different between the two groups at any time point. CCS was a significant predictor of overall QoL (β = -1.82, p < 0.0001), social-emotional (β = -1.76, p < 0.0001), physical (β = -1.12, p < 0.0001) and overall functions (β = -1.15, p < 0.0001) at a multivariate level. Taste was reported as an important symptom for both tube-fed and orally fed groups at end of treatment and follow-up. CONCLUSIONS: TSAs are an important symptom and an independent predictor of QoL for both tube-fed and orally fed HNC patients. HNC patients need support to manage TSAs, regardless of the method of nutritional intake.
PURPOSE: Taste and smell alterations (TSAs) are among the most frequent and troublesome symptoms reported by head and neck cancer (HNC) patients after treatment. Little is known about the relationship between TSAs and quality of life (QoL) among HNC patients. The aim of this study was to determine the effect of TSAs on overall QoL among tube-fed and orally fed HNC patients before treatment, at end of treatment and at 2.5-month follow-up. METHODS: Data were collected in a longitudinal study prior to treatment (n = 126), at end of treatment (n = 100) and at 2.5-month follow-up (n = 85). Chemosensory Complaint Score (CCS) and the University of Washington Quality of Life Questionnaire version 3 were used to assess TSAs and QoL, respectively. Generalized estimated equation modeling was used to estimate the effect of CCS on QoL. RESULTS: At end of treatment, QoL and CCS had declined for both tube-fed and orally fed patients and thereafter improved, but not to pre-treatment levels. Neither QoL nor CCS mean scores were different between the two groups at any time point. CCS was a significant predictor of overall QoL (β = -1.82, p < 0.0001), social-emotional (β = -1.76, p < 0.0001), physical (β = -1.12, p < 0.0001) and overall functions (β = -1.15, p < 0.0001) at a multivariate level. Taste was reported as an important symptom for both tube-fed and orally fed groups at end of treatment and follow-up. CONCLUSIONS: TSAs are an important symptom and an independent predictor of QoL for both tube-fed and orally fed HNC patients. HNC patients need support to manage TSAs, regardless of the method of nutritional intake.
Entities:
Keywords:
Head and neck cancer; Quality of life; Radiation therapy; Self-report; Smell; Taste; Tube feeding
Authors: Allan J Hovan; P Michele Williams; Peter Stevenson-Moore; Yula B Wahlin; Kirsten E O Ohrn; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-05-22 Impact factor: 3.603
Authors: R S Wickham; M Rehwaldt; C Kefer; S Shott; K Abbas; E Glynn-Tucker; C Potter; C Blendowski Journal: Oncol Nurs Forum Date: 1999-05 Impact factor: 2.172
Authors: M A List; J Stracks; L Colangelo; P Butler; N Ganzenko; D Lundy; P Sullivan; D Haraf; M Kies; W Goodwin; E E Vokes Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: T Rampling; H King; K L Mais; G M Humphris; R Swindell; A Sykes; N Slevin Journal: Clin Oncol (R Coll Radiol) Date: 2003-06 Impact factor: 4.126
Authors: Christine G Gourin; Brian J Boyce; Creighton C Vaught; Lori M Burkhead; Robert H Podolsky Journal: Laryngoscope Date: 2009-05 Impact factor: 3.325
Authors: Sonia A Duffy; Jeffrey E Terrell; Marcia Valenstein; David L Ronis; Laurel A Copeland; Mary Connors Journal: Gen Hosp Psychiatry Date: 2002 May-Jun Impact factor: 3.238
Authors: Marianne Boll Kristensen; Tina Broby Mikkelsen; Anne Marie Beck; Ann-Dorthe Zwisler; Irene Wessel; Karin B Dieperink Journal: J Cancer Surviv Date: 2019-08-24 Impact factor: 4.442
Authors: Paule V Joseph; Alissa Nolden; Kord M Kober; Steven M Paul; Bruce A Cooper; Yvette P Conley; Marilyn J Hammer; Fay Wright; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2020-11-28 Impact factor: 5.576
Authors: Marianne Boll Kristensen; Irene Wessel; Anne Marie Beck; Karin B Dieperink; Tina Broby Mikkelsen; Jens-Jakob Kjer Møller; Ann-Dorthe Zwisler Journal: Nutrients Date: 2020-07-17 Impact factor: 5.717
Authors: Stefan Rauh; Andrea Antonuzzo; Paolo Bossi; Robert Eckert; Marie Fallon; Anna Fröbe; Silvia Gonella; Raffaele Giusti; Gabor Lakatos; Daniele Santini; Anna Villarini Journal: ESMO Open Date: 2018-05-05